<!DOCTYPE html >
<html lang="en">
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p153" style="overflow: hidden; position: relative; background-color: white; width: 433px; height: 649px;">

<!-- Begin shared CSS values -->
<style class="shared-css" type="text/css" >
.t {
	-webkit-transform-origin: top left;
	-moz-transform-origin: top left;
	-o-transform-origin: top left;
	-ms-transform-origin: top left;
	-webkit-transform: scale(0.25);
	-moz-transform: scale(0.25);
	-o-transform: scale(0.25);
	-ms-transform: scale(0.25);
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
}
</style>
<!-- End shared CSS values -->


<!-- Begin inline CSS -->
<style type="text/css" >

#t1_153{left:411px;top:233px;letter-spacing:-0.1px;}
#t2_153{left:411px;top:78px;letter-spacing:-0.3px;}
#t3_153{left:413px;top:630px;letter-spacing:-0.2px;}
#t4_153{left:65px;top:40px;letter-spacing:-1px;}
#t5_153{left:65px;top:75px;letter-spacing:-0.9px;word-spacing:-0.5px;}
#t6_153{left:65px;top:93px;letter-spacing:-1px;word-spacing:4.2px;}
#t7_153{left:65px;top:108px;letter-spacing:-1px;word-spacing:-0.2px;}
#t8_153{left:65px;top:125px;letter-spacing:-1px;word-spacing:-0.5px;}
#t9_153{left:65px;top:156px;letter-spacing:-1px;word-spacing:-0.3px;}
#ta_153{left:74px;top:173px;letter-spacing:-0.8px;word-spacing:-0.5px;}
#tb_153{left:82px;top:190px;letter-spacing:-1px;word-spacing:2.2px;}
#tc_153{left:82px;top:206px;letter-spacing:-1px;word-spacing:-0.1px;}
#td_153{left:82px;top:223px;letter-spacing:-1px;word-spacing:1.8px;}
#te_153{left:82px;top:238px;letter-spacing:-1px;}
#tf_153{left:82px;top:256px;letter-spacing:-1px;word-spacing:2.3px;}
#tg_153{left:82px;top:271px;letter-spacing:-0.8px;}
#th_153{left:74px;top:289px;letter-spacing:-1px;}
#ti_153{left:81px;top:289px;letter-spacing:-1px;}
#tj_153{left:143px;top:289px;letter-spacing:-1px;word-spacing:-1.5px;}
#tk_153{left:81px;top:304px;letter-spacing:-1px;word-spacing:-0.1px;}
#tl_153{left:74px;top:321px;letter-spacing:-0.9px;word-spacing:-0.5px;}
#tm_153{left:74px;top:339px;letter-spacing:-1px;word-spacing:-0.1px;}
#tn_153{left:74px;top:356px;letter-spacing:-1px;word-spacing:1.7px;}
#to_153{left:74px;top:372px;letter-spacing:-0.9px;word-spacing:-0.2px;}
#tp_153{left:74px;top:389px;letter-spacing:-0.9px;}
#tq_153{left:82px;top:406px;letter-spacing:-1px;}
#tr_153{left:94px;top:406px;letter-spacing:-1px;word-spacing:14.3px;}
#ts_153{left:94px;top:422px;letter-spacing:-0.9px;word-spacing:6px;}
#tt_153{left:94px;top:437px;letter-spacing:-1px;word-spacing:3.9px;}
#tu_153{left:258px;top:437px;letter-spacing:-0.9px;word-spacing:3.7px;}
#tv_153{left:94px;top:452px;letter-spacing:-1px;word-spacing:-0.1px;}
#tw_153{left:94px;top:468px;letter-spacing:-1px;word-spacing:6.3px;}
#tx_153{left:94px;top:483px;letter-spacing:-0.9px;word-spacing:-0.3px;}
#ty_153{left:135px;top:483px;letter-spacing:-0.5px;}
#tz_153{left:82px;top:500px;letter-spacing:-1px;}
#t10_153{left:94px;top:500px;letter-spacing:-1px;word-spacing:12.2px;}
#t11_153{left:94px;top:516px;letter-spacing:-1px;word-spacing:-0.1px;}
#t12_153{left:82px;top:533px;letter-spacing:-1px;}
#t13_153{left:94px;top:533px;letter-spacing:-1px;}
#t14_153{left:94px;top:548px;letter-spacing:-1px;word-spacing:-0.1px;}
#t15_153{left:292px;top:548px;letter-spacing:-1px;word-spacing:-0.1px;}
#t16_153{left:94px;top:563px;letter-spacing:-1px;word-spacing:3.1px;}
#t17_153{left:94px;top:579px;letter-spacing:-1px;word-spacing:0.1px;}
#t18_153{left:381px;top:579px;letter-spacing:-1px;}

.s1_153{
	FONT-SIZE: 48.9px;
	FONT-FAMILY: AllerDisplay_lq;
	color: rgb(156,100,158);
}

.s2_153{
	FONT-SIZE: 48.9px;
	FONT-FAMILY: AllerDisplay_lq;
	color: rgb(35,31,32);
}

.s3_153{
	FONT-SIZE: 37.6px;
	FONT-FAMILY: AllerDisplay_lq;
	color: rgb(255,255,255);
}

.s4_153{
	FONT-SIZE: 48.9px;
	FONT-FAMILY: Helvetica-Condensed_ix;
	color: rgb(35,31,32);
}

.s5_153{
	FONT-SIZE: 48.9px;
	FONT-FAMILY: Helvetica-Condensed-Bold_j0;
	color: rgb(35,31,32);
}

.s6_153{
	FONT-SIZE: 48.9px;
	FONT-FAMILY: HelveticaNeue-LightCondOb_j8;
	color: rgb(35,31,32);
}

.t.m0_153{
	-webkit-transform: matrix(0,-1,1,0,0, 0) scale(0.25);
	-ms-transform: matrix(0,-1,1,0,0, 0) scale(0.25);
	-moz-transform: matrix(0,-1,1,0,0, 0) scale(0.25);
	-o-transform: matrix(0,-1,1,0,0, 0) scale(0.25);
}

</style>
<!-- End inline CSS -->

<!-- Begin embedded font definitions -->
<style id="fonts153" type="text/css" >

@font-face {
	font-family: HelveticaNeue-LightCondOb_j8;
	src: url("fonts/HelveticaNeue-LightCondOb_j8.woff") format("woff");
}

@font-face {
	font-family: Helvetica-Condensed-Bold_j0;
	src: url("fonts/Helvetica-Condensed-Bold_j0.woff") format("woff");
}

@font-face {
	font-family: AllerDisplay_lq;
	src: url("fonts/AllerDisplay_lq.woff") format("woff");
}

@font-face {
	font-family: Helvetica-Condensed_ix;
	src: url("fonts/Helvetica-Condensed_ix.woff") format("woff");
}

</style>
<!-- End embedded font definitions -->

<!-- Begin page background -->
<div id="pg153Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg153" style="-webkit-user-select: none;"><object width="433" height="649" data="153/153.svg" type="image/svg+xml" id="pdf153" style="width:433px; height:649px; -moz-transform:scale(1); z-index: 0;"></object></div>
<!-- End page background -->


<!-- Begin text definitions (Positioned/styled in CSS) -->
<div id="t1_153" class="t m0_153 s1_153">O Guia do Jovem Internista </div>
<div id="t2_153" class="t m0_153 s2_153">2016</div>
<div id="t3_153" class="t s3_153">151</div>
<div id="t4_153" class="t s4_153">Descontinuar profilaxia: &gt; 3meses de CD4&gt;100cels/μL sob TARV </div>
<div id="t5_153" class="t s5_153">- Esquemas:</div>
<div id="t6_153" class="t s4_153">Azitromicina 1200 mg/1xsemana ou 600mg 2xsemana ou Claritromi-</div>
<div id="t7_153" class="t s4_153">cina 500mg 2xdia</div>
<div id="t8_153" class="t s4_153">Alternativas: Rifabutina 300mg 1xdia (apenas se exclusão de TB activa)</div>
<div id="t9_153" class="t s5_153">• Cryptococcus neoformans</div>
<div id="ta_153" class="t s5_153">• Clínica: </div>
<div id="tb_153" class="t s4_153">Meningoencefalite - cefaleia, febre, letargia, défices sensitivos e de </div>
<div id="tc_153" class="t s4_153">memória, paresias de nervos cranianos</div>
<div id="td_153" class="t s4_153">Criptococose pulmonar - tosse, expectoração, toracalgia, criptoco-</div>
<div id="te_153" class="t s4_153">comas</div>
<div id="tf_153" class="t s4_153">Lesões cutâneas - placas, papulas, púrpura, vesículas, exantemas, </div>
<div id="tg_153" class="t s4_153">tumores </div>
<div id="th_153" class="t s5_153">• </div>
<div id="ti_153" class="t s5_153">Diagnóstico:</div>
<div id="tj_153" class="t s4_153">Isolamento de C. Neoformans em tecido normalmente </div>
<div id="tk_153" class="t s4_153">estéril (LCR, sangue, pele)</div>
<div id="tl_153" class="t s5_153">• Tratamento:</div>
<div id="tm_153" class="t s4_153">Pulmonar - Fluconazol 400mg/dia 12 meses</div>
<div id="tn_153" class="t s4_153">Extra-pulmonar ou pulmonar difusa - Anfotericina B 0,5 a 1,0mg/kg/</div>
<div id="to_153" class="t s4_153">dia 4-6 semanas</div>
<div id="tp_153" class="t s4_153">Meningoencefalite: </div>
<div id="tq_153" class="t s4_153">1. </div>
<div id="tr_153" class="t s4_153">Indução (pelo menos 2 semanas): Anfotericina B desoxico-</div>
<div id="ts_153" class="t s4_153">lato 0,7 a 1 mg/kg/dia com ou sem Flucitosina 100 mg/kg/dia </div>
<div id="tt_153" class="t s4_153">dividida em quatro tomas diárias. (</div>
<div id="tu_153" class="t s6_153">Considerar o prolongamento do </div>
<div id="tv_153" class="t s6_153">tempo de indução em pacientes comatosos ou com deterioração clínica, </div>
<div id="tw_153" class="t s6_153">PIC persistentemente elevada, cultura liquor positiva após 2 semanas </div>
<div id="tx_153" class="t s6_153">de terapia</div>
<div id="ty_153" class="t s4_153">). </div>
<div id="tz_153" class="t s4_153">2. </div>
<div id="t10_153" class="t s4_153">Consolidação (8 semanas): Fluconazol 400mg/dia, alternativa </div>
<div id="t11_153" class="t s4_153">Itraconazol 200mg 2Xdia</div>
<div id="t12_153" class="t s4_153">3. </div>
<div id="t13_153" class="t s4_153">Manutenção (até doente assintomático e CD4+ &gt;200/μL por pelo </div>
<div id="t14_153" class="t s4_153">menos 12 meses): Fluconazol 200mg/dia. (</div>
<div id="t15_153" class="t s6_153">Anfotericina desoxicola-</div>
<div id="t16_153" class="t s6_153">to (1 mg/kg/semana) pode ser considerado como terapia de manuten-</div>
<div id="t17_153" class="t s6_153">ção, mas maior recidiva e toxicidade quando comparada ao ﬂuconazol</div>
<div id="t18_153" class="t s4_153">).</div>

<!-- End text definitions -->


</div>
</body>
</html>
